Immunocore/$IMCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Ticker
$IMCR
Sector
Primary listing
Employees
493
Headquarters
Website
Immunocore Metrics
BasicAdvanced
$1.7B
-
-$0.41
0.77
-
Price and volume
Market cap
$1.7B
Beta
0.77
52-week high
$39.33
52-week low
$23.15
Average daily volume
298K
Financial strength
Current ratio
5.893
Quick ratio
5.601
Long term debt to equity
111.877
Total debt to equity
112.351
Interest coverage (TTM)
-1.63%
Profitability
EBITDA (TTM)
-24.559
Gross margin (TTM)
92.32%
Net profit margin (TTM)
-5.70%
Operating margin (TTM)
-7.97%
Effective tax rate (TTM)
9.07%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
-1.69%
Return on equity (TTM)
-5.43%
Valuation
Price to revenue (TTM)
4.815
Price to book
4.44
Price to tangible book (TTM)
4.44
Price to free cash flow (TTM)
60.276
Free cash flow yield (TTM)
1.66%
Free cash flow per share (TTM)
0.568
Growth
Revenue change (TTM)
26.78%
Earnings per share change (TTM)
-63.34%
3-year revenue growth (CAGR)
57.14%
3-year earnings per share growth (CAGR)
-47.90%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Bulls say / Bears say
KIMMTRAK net product sales reached $98.0 million in Q2 2025, a 30% year-over-year increase driven by a 15% uplift in the U.S. and strong demand in Europe (Nasdaq)
Cash, cash equivalents and marketable securities totaled $882.8 million as of June 30, 2025, up from $820.4 million at year-end 2024, ensuring substantial runway for ongoing clinical trials (Nasdaq)
The Phase 3 TEBE-AM trial is on track to complete enrollment in the first half of 2026; dose selection for the PRISM-MEL-301 trial is expected in the second half of 2025, and Phase 1 HBV data for IMC-I109V will be presented at AASLD 2025, demonstrating solid clinical progress (Nasdaq)
Net loss of $10.3 million in Q2 2025, alongside R&D expenses of $69.0 million and SG&A of $42.8 million, highlights continued pressure on profitability and margins (Nasdaq)
Topline data from pivotal Phase 3 trials (TEBE-AM and PRISM-MEL-301) are not expected until 2026, delaying the prospect of additional revenue streams beyond KIMMTRAK (Nasdaq)
Expected payment of approximately $65 million in sales-related rebate accruals in the second half of 2025 may significantly erode cash reserves and limit financial flexibility (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunocore stock?
Immunocore (IMCR) has a market cap of $1.7B as of October 08, 2025.
What is the P/E ratio for Immunocore stock?
The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of October 08, 2025.
Does Immunocore stock pay dividends?
No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Immunocore dividend payment date?
Immunocore (IMCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunocore?
Immunocore (IMCR) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.